Natalie Kreitzer1, Rachel Ancona, Cheryl McCullumsmith, Brad G Kurowski, Brandon Foreman, Laura B Ngwenya, Opeolu Adeoye. 1. Division of Neurocritical Care (Drs Kreitzer, Foreman, and Adeoye), Department of Emergency Medicine (Drs Kreitzer and Adeoye and Ms Ancona), Department of Psychiatry (Dr McCullumsmith), Department of Pediatrics (Dr Kurowski), Department of Physical Medicine and Rehabilitation (Dr Kurowski), Department of Neurology and Rehabilitation Medicine (Drs Foreman and Ngwenya), and Department of Neurosurgery (Dr Ngwenya), University of Cincinnati, Cincinnati, Ohio.
Abstract
OBJECTIVE: Following traumatic brain injury (TBI), depressive symptoms are common and may influence recovery. We performed a meta-analysis to estimate the benefit of antidepressants following TBI and compare the estimated effects between antidepressants and placebo. PARTICIPANTS: Multiple databases were searched to find prospective pharmacological treatment studies of major depressive disorder (MDD) in adults following TBI. MAIN MEASURES: Effect sizes for antidepressant medications in patients with TBI were calculated for within-subjects designs that examined change from baseline after receiving medical treatment and treatment/placebo designs that examined the differences between the antidepressants and placebo groups. DESIGN: A random-effects model was used for both analyses. RESULTS: Of 1028 titles screened, 11 were included. Pooled estimates showed nonsignificant difference in reduction of depression scores between medications and placebo (standardized mean difference of 5 trials = -0.3; 95% CI, -0.6 to 0.0; I = 17%), and a significant reduction in depression scores for individuals after pharmacotherapy (mean change = -11.2; 95% CI, -14.7 to -7.6 on the Hamilton Depression Scale; I = 87%). CONCLUSIONS: This meta-analysis found no significant benefit of antidepressant over placebo in the treatment of MDD following TBI. Pooled estimates showed a high degree of bias and heterogeneity. Prospective studies on the impact of antidepressants in well-defined cohorts of TBI patients are warranted.
OBJECTIVE: Following traumatic brain injury (TBI), depressive symptoms are common and may influence recovery. We performed a meta-analysis to estimate the benefit of antidepressants following TBI and compare the estimated effects between antidepressants and placebo. PARTICIPANTS: Multiple databases were searched to find prospective pharmacological treatment studies of major depressive disorder (MDD) in adults following TBI. MAIN MEASURES: Effect sizes for antidepressant medications in patients with TBI were calculated for within-subjects designs that examined change from baseline after receiving medical treatment and treatment/placebo designs that examined the differences between the antidepressants and placebo groups. DESIGN: A random-effects model was used for both analyses. RESULTS: Of 1028 titles screened, 11 were included. Pooled estimates showed nonsignificant difference in reduction of depression scores between medications and placebo (standardized mean difference of 5 trials = -0.3; 95% CI, -0.6 to 0.0; I = 17%), and a significant reduction in depression scores for individuals after pharmacotherapy (mean change = -11.2; 95% CI, -14.7 to -7.6 on the Hamilton Depression Scale; I = 87%). CONCLUSIONS: This meta-analysis found no significant benefit of antidepressant over placebo in the treatment of MDD following TBI. Pooled estimates showed a high degree of bias and heterogeneity. Prospective studies on the impact of antidepressants in well-defined cohorts of TBI patients are warranted.
Authors: Tracey Holsinger; David C Steffens; Caroline Phillips; Michael J Helms; Richard J Havlik; John C S Breitner; Jack M Guralnik; Brenda L Plassman Journal: Arch Gen Psychiatry Date: 2002-01
Authors: Chi-Hua Chen; John Suckling; Cinly Ooi; Cynthia H Y Fu; Steve C R Williams; Nicholas D Walsh; Martina T Mitterschiffthaler; Emilio Merlo Pich; Ed Bullmore Journal: Neuropsychopharmacology Date: 2007-11-07 Impact factor: 7.853
Authors: Michelle D Failla; Josh N Burkhardt; Megan A Miller; Joelle M Scanlon; Yvette P Conley; Robert E Ferrell; Amy K Wagner Journal: Brain Inj Date: 2013-04-05 Impact factor: 2.311
Authors: Anbesaw W Selassie; Eduard Zaloshnja; Jean A Langlois; Ted Miller; Paul Jones; Claudia Steiner Journal: J Head Trauma Rehabil Date: 2008 Mar-Apr Impact factor: 2.710
Authors: Jerome J Maller; Richard H S Thomson; Kerstin Pannek; Neil Bailey; Philip M Lewis; Paul B Fitzgerald Journal: Behav Brain Res Date: 2014-06-02 Impact factor: 3.332
Authors: Sean M Collins; Christopher J O'Connell; Evan L Reeder; Sophia V Norman; Kainat Lungani; Poornima Gopalan; Gary A Gudelsky; Matthew J Robson Journal: Front Pharmacol Date: 2022-07-15 Impact factor: 5.988